NCT01602549View on ClinicalTrials.gov

A Study to Assess the Effect of Repeat Doses of GSK962040 on the Pharmacokinetics of L-DOPA in Subjects With Parkinson's Disease Exhibiting Delayed Gastric Emptying

PHASE2CompletedINTERVENTIONAL
Enrollment

58

Participants

Timeline

Start Date

July 31, 2012

Primary Completion Date

May 31, 2014

Study Completion Date

May 31, 2014

Conditions
Gastroparesis
Interventions
DRUG

GSK962040 (25 mg tablet)

25 mg tablet

DRUG

Placebo

matching placebo tablet

Trial Locations (11)

2031

GSK Investigational Site, Randwick

13088

GSK Investigational Site, Berlin

44791

GSK Investigational Site, Bochum

50937

GSK Investigational Site, Cologne

53105

GSK Investigational Site, Bonn

89081

GSK Investigational Site, Ulm

07747

GSK Investigational Site, Jena

SE-751 85

GSK Investigational Site, Uppsala

C2B 2PY

GSK Investigational Site, Cambridge

NE4 5PL

GSK Investigational Site, Newcastle upon Tyne

NR4 7UY

GSK Investigational Site, Norwich

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT01602549 - A Study to Assess the Effect of Repeat Doses of GSK962040 on the Pharmacokinetics of L-DOPA in Subjects With Parkinson's Disease Exhibiting Delayed Gastric Emptying | Biotech Hunter | Biotech Hunter